🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

surfingmash.com/s5-e01-1-surfi… After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Jörn Schattenberg describes the challenges, opportunities and experiences that he has found in assuming Department leadership at the University of the

Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease Check out👉- Journal of Hepatology 👉How to use and interpret repeated Fibroscan journal-of-hepatology.eu/article/S0168-… Katrine H. Thorhauge @GeorgSemmler

Nordic Metabolomics Society Nordic Metabolomics Society has three travel grants available for #earlycareer researchers, for travel to #MetSoc2024 in Osaka. DL March 15. See the society front page. And, repeating, #NMetC2024 (Turku, Aug 26-28) pages are now open. nordicmetsoc.org

surfingmash.com/s5-4-masld-epi… Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients. #MASLDepidemiology, #GlobalNASHCouncil #NASHpodcast

Madrigal is proud to announce the approval of the first and only therapy in NASH/MASH. Learn more about the milestone by reading our press release: bit.ly/3Pmyqwr #NASH

surfingmash.com/s5-e09-value-o… Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management. #VCTE #FibroScan #InOfficeMonitoring

The first #MASH drug therapy on the horizon: Current perspectives of #resmetirom→jmp.sh/e1HVAF1H via Salvatore Petta Stefano Romeo Utpal Pajvani Minghua Zheng Alessio Aghemo Luca Valenti Liver International #MASLD #NAFLD #NASH #livertwitter

🗺 On #WorldLiverDay, let's meet the IMI/IHI projects working to tackle #LiverDisease! ✅ LITMUS is exploring how simple blood tests or scans could replace invasive biopsies as a way to identify people with MASH (previously known as NASH). 👉 europa.eu/!DfWNBw

It's #WorldLiverDay and we're incredibly excited to share in Nature Medicine: "Opportunities and challenges following approval of resmetirom for MASH liver disease". - what we believe is a roadmap for MASH drug roll-out. nature.com/articles/s4159…

Want to learn more about the largest clinical trial in hepatology #LiverTwitter? LiverAim 📌A new trial of 100,000 📌Utilization of three existing European Commission consortia: LiverScreen H2020 GALAXY LITMUS_Project ihi.europa.eu/news-events/ne…

The LITMUS consortium is shocked and saddened to hear of the passing of our friend and collaborator Stephen Harrison. Our thoughts are with his family and colleagues.

EASLnews I was so sad to learn of Stephen’s untimely passing - a great friend, colleague and true giant of hepatology. His legacy in #MASH will benefit patients for generations. My thoughts are with his many friends but especially his wife Renee and children. AASLD LITMUS_Project

Let's talk liver health! Dive into our survey and help unravel the complexities of steatotic (fatty) liver disease. Your input drives progress. Start here ➡️ surveymonkey.com/r/5SRW5YX #LiverTalks #ResearchRevolution #livertwitter #raiseawareness #liverdisease

To mark the end of the LITMUS project, we have produced this weighty tome gathering most of the peer-reviewed journal papers arising from the project (over 60 in total). Many more papers are in preparation or planned! Innovative Health Initiative EFPIA

Are the AGILE scores winning the battle for second tier NIT testing? Check out this paper on AGILE 3+/4 , it looks convincing across the SLD spectrum!! More correctly classified patients- less FP’s.

Ever wondered WHY eating healthy is beneficial for your liver? 🥦🫘=🧪=🤎💪 New study from UK Biobank in JHEP Reports associated EAT-Lancet diet to changes in 81 metabolites, potentially underlying diet's protective mechanism against MASLD jhep-reports.eu/article/S2589-…

Which preclinical model best recapitulates #MASLD metabolic/fibrosing aspects? Does an ideal model exist? The LITMUS_Project Preclinical Group screened the phenotype, histopathology and transcriptome of common murine MASLD models benchmarked against humans nature.com/articles/s4225…

The LITMUS_Project Histopathology Group 🔬🧬scored >1️⃣0️⃣0️⃣0️⃣ samples and devised the 🥇Human Histology Proximity Score for approximation of murine #MASLD histology to human! Multidisciplinary work at its best 💪🏻💪🏻! European Society of Pathology (ESP) University of Athens Newcastle University EASLnews UK Liver Pathology Group

Online now! No single perfect mouse model of MASH dlvr.it/T8C8sp

My commentary on a herculean study from the LITMUS groups out in Nature Metabolism characterizing multiple different mouse MASH models. Unsurprisingly, no single model emerges as the “best” - the human disease is complex and heterogeneous, and mice aren’t human. But I think this